Breast cancer is the second greatest cause of death among women worldwide; it comprises
a group of heterogeneous diseases that evolves due to uncontrolled cellular growth and …

Estrogen receptor α (ER) is the major driver of∼ 75% of breast cancers, and multiple ER
targeting drugs are routinely used clinically to treat patients with ER+ breast cancer …

Progesterone receptor (PR) expression is used as a biomarker of oestrogen receptor-α
(ERα) function and breast cancer prognosis. Here we show that PR is not merely an ERα …

Most breast cancers are driven by oestrogen receptor-α. Anti-oestrogenic drugs are the
standard treatment for these breast cancers; however, treatment resistance is common …

Most breast cancers are driven by a transcription factor called oestrogen receptor (ER).
Understanding the mechanisms of ER activity in breast cancer has been a major research …

Hormone receptor positive tumors represent the most common form of breast cancer and
account for most of the deaths from the disease. Endocrine therapy represents the main …

Breast cancer is the most common cancer among women and is considered a developed
country disease. Moreover, is a heterogenous disease, existing different types and stages of …

Background: Advanced hormone-receptor positive HER2 negative breast cancer is a
common and a very heterogeneous disease. Hormone therapy is the main first line …

Purpose Venous thromboembolism (VTE) is the second most common cause of death in
hospitalized patients with cancer, and cancer treatments may exacerbate VTE risk. Patients …

Breast cancer is the most commonly diagnosed cancer worldwide. More than 200,000 new
cases of invasive breast cancer are diagnosed annually in the United States; approximately …